Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

All is not lost--the improving outcome of patients with chronic lymphocytic leukaemia failing frontline therapy with fludarabine, cyclophosphamide and rituximab.

Cheah CY, Lew TE, Lee R, Tam CS, Seymour JF, Carney DA.

Eur J Haematol. 2013 Aug;91(2):189-90. doi: 10.1111/ejh.12138. Epub 2013 Jun 28. No abstract available.

PMID:
23668259
2.

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab.

Fink AM, Böttcher S, Ritgen M, Fischer K, Pflug N, Eichhorst B, Wendtner CM, Winkler D, Bühler A, Zenz T, Staib P, Mayer J, Hensel M, Hopfinger G, Wenger M, Fingerle-Rowson G, Döhner H, Kneba M, Stilgenbauer S, Busch R, Hallek M.

Leukemia. 2013 Sep;27(9):1949-52. doi: 10.1038/leu.2013.190. Epub 2013 Jun 21. No abstract available.

3.

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Geisler CH, Montillo M, Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, Saville MW, Valente N, Wenger MK, Moiseev SI.

J Clin Oncol. 2010 Apr 1;28(10):1756-65. doi: 10.1200/JCO.2009.26.4556. Epub 2010 Mar 1.

PMID:
20194844
4.
5.

The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab.

Panovská A, Smolej L, Lysák D, Brychtová Y, Šimkovič M, Motyčková M, Vodárek P, Lindtnerová M, Trbušek M, Malčíková J, Pospíšilová Š, Mayer J, Doubek M.

Eur J Haematol. 2013 Jun;90(6):479-85. doi: 10.1111/ejh.12106. Epub 2013 Apr 27.

PMID:
23506191
6.

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jäger U, Bergmann M, Stilgenbauer S, Schweighofer C, Wendtner CM, Döhner H, Brittinger G, Emmerich B, Hallek M; German CLL Study Group.

Blood. 2006 Feb 1;107(3):885-91. Epub 2005 Oct 11.

7.

Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.

Robak T, Lech-Maranda E, Robak P.

Expert Rev Anticancer Ther. 2010 Oct;10(10):1529-43. doi: 10.1586/era.10.132. Review.

PMID:
20942624
8.

Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned?

Ahmadi T, Schuster SJ.

J Clin Oncol. 2009 Feb 1;27(4):479-80. doi: 10.1200/JCO.2008.18.8698. Epub 2008 Dec 15. No abstract available.

PMID:
19075263
9.

Advancing therapy for chronic lymphocytic leukemia--the role of rituximab.

Hillmen P.

Semin Oncol. 2004 Feb;31(1 Suppl 2):22-6. Review.

PMID:
15042531
10.

Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.

Hendry L, Bowen A, Matutes E, Swansbury J, Catovsky D.

Leuk Lymphoma. 2004 May;45(5):945-50.

PMID:
15291353
11.

A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.

Hillmen P, Cohen DR, Cocks K, Pettitt A, Sayala HA, Rawstron AC, Kennedy DB, Fegan C, Milligan DW, Radford J, Mercieca J, Dearden C, Ezekwisili R, Smith AF, Brown J, Booth GA, Varghese AM, Pocock C; NCRI CLL Sub-Group.

Br J Haematol. 2011 Mar;152(5):570-8. doi: 10.1111/j.1365-2141.2010.08317.x. Epub 2011 Jan 14.

PMID:
21231927
12.

Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.

Foon KA, Boyiadzis M, Land SR, Marks S, Raptis A, Pietragallo L, Meisner D, Laman A, Sulecki M, Butchko A, Schaefer P, Lenzer D, Tarhini A.

J Clin Oncol. 2009 Feb 1;27(4):498-503. doi: 10.1200/JCO.2008.17.2619. Epub 2008 Dec 15.

PMID:
19075274
13.

Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.

Marotta G, Bigazzi C, Lenoci M, Tozzi M, Bocchia M, Lauria F.

Haematologica. 2000 Dec;85(12):1268-70.

14.

Rituximab therapy of severe aplastic anemia induced by fludarabine and cyclophosphamide in a patient affected by B-cell chronic lymphocytic leukemia.

Castiglioni MG, Scatena P, Pandolfo C, Mechelli S, Bianchi M.

Leuk Lymphoma. 2006 Sep;47(9):1985-6. No abstract available.

PMID:
17065021
15.

Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas.

Zaja F, Rogato A, Russo D, Marin L, Silvestri F, Baccarani M.

Eur J Haematol. 1997 Nov;59(5):327-8. No abstract available.

PMID:
9414645
16.

Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.

Borthakur G, O'Brien S, Wierda WG, Thomas DA, Cortes JE, Giles FJ, Kantarjian HM, Lerner S, Keating MJ.

Br J Haematol. 2007 Mar;136(6):800-5.

PMID:
17341265
17.

Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.

Lepretre S, Aurran T, Mahé B, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Letestu R, Cymbalista F, Feugier P.

Blood. 2012 May 31;119(22):5104-10. doi: 10.1182/blood-2011-07-365437. Epub 2012 Feb 14.

18.

Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia.

Foon KA, Mehta D, Lentzsch S, Kropf P, Marks S, Lenzner D, Pietragallo L, Sulecki M, Tarhini A, Boyiadzis M.

Blood. 2012 Mar 29;119(13):3184-5. doi: 10.1182/blood-2012-01-408047. No abstract available.

19.

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.

O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR.

J Clin Oncol. 2007 Mar 20;25(9):1114-20. Epub 2007 Feb 12. Erratum in: J Clin Oncol. 2008 Feb 10;26(5):820.

PMID:
17296974
20.

Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia.

Schiavone EM, De Simone M, Palmieri S, Annunziata M, Pocali B, Copia C, D'Amico MR, Vecchio LD, Ferrara F.

Eur J Haematol. 2003 Jul;71(1):23-8.

PMID:
12801295

Supplemental Content

Support Center